Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $538875.0.

  • BioRestorative Therapies' Accumulated Expenses fell 2101.35% to $538875.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $538875.0, marking a year-over-year decrease of 2101.35%. This contributed to the annual value of $704000.0 for FY2024, which is 108.0% down from last year.
  • Per BioRestorative Therapies' latest filing, its Accumulated Expenses stood at $538875.0 for Q3 2025, which was down 2101.35% from $359250.0 recorded in Q2 2025.
  • BioRestorative Therapies' 5-year Accumulated Expenses high stood at $1.2 million for Q1 2021, and its period low was $114647.0 during Q3 2022.
  • Moreover, its 5-year median value for Accumulated Expenses was $416973.5 (2023), whereas its average is $449789.9.
  • Per our database at Business Quant, BioRestorative Therapies' Accumulated Expenses tumbled by 8392.02% in 2022 and then soared by 44714.77% in 2023.
  • BioRestorative Therapies' Accumulated Expenses (Quarter) stood at $134970.0 in 2021, then decreased by 3.63% to $130072.0 in 2022, then surged by 447.15% to $711686.0 in 2023, then decreased by 1.08% to $704000.0 in 2024, then dropped by 23.46% to $538875.0 in 2025.
  • Its last three reported values are $538875.0 in Q3 2025, $359250.0 for Q2 2025, and $179625.0 during Q1 2025.